Nirvana Life Sciences Inc.
NIRVF
$0.0083
$0.000.00%
| Weiss Ratings | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.40% | |||
| 30-Day Total Return | 0.40% | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | 0.40% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.01 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Jan 30, 2025 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 167.34K | |||
| Enterprise Value | 230.33K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -76.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.45 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -5.31 | |||
| Enterprise Value/EBIT | -5.09 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 48.23M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604-401-8100 | |||
| Address | 650 West Georgia Street Vancouver, BC V6B 4N8 | |||
| Website | nirvanalifescience.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -227.91% | |||
| Return on Equity | -- | |||
| Income Statement | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -323.20K | |||
| EBIT (TTM) | -337.30K | |||
| Net Income (TTM) | -338.00K | |||
| Net Income Avl. to Common (TTM) | -338.00K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 63.88% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 65.38% | |||
| Balance Sheet | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 400.00 | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 14.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -890.80K | |||
| Current Ratio (Q) | 0.015 | |||
| Book Value Per Share (Q) | -$0.02 | |||
| Total Assets (Q) | 140.50K | |||
| Total Current Liabilities (Q) | 906.30K | |||
| Total Debt (Q) | 49.60K | |||
| Total Liabilities (Q) | 1.03M | |||
| Total Common Equity (Q) | -886.90K | |||
| Cash Flow | NIRVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 36.30K | |||
| Net Change in Cash (TTM) | -7.40K | |||
| Levered Free Cash Flow (TTM) | 92.20K | |||
| Cash from Operations (TTM) | -32.40K | |||
